Threshold Pharmaceuticals, Inc (THLD): Opiniones

Mas de lo mismo,thld es el dia de la marmota,no he visto nunca nada igual. Que accion mas puerca,tiene menos fuerza que un muelle de cuerda.

En el tablon de Yahoo colgaron esto hace 1 hora:

Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.

Background: Tumors often consist of highly hypoxic subregions known to be resistant to chemotherapy and radiotherapy. TH-302 is an investigational hypoxia-targeted drug with a 2-nitroimidazole trigger designed to release the DNA alkylator bromo-isophosphoramide mustard (Br-IPM) when reduced in severe hypoxia. Preclinical models demonstrate that treatment with sunitinib increased the tumor hypoxic fraction, the therapeutic target of TH-302. Initiating TH-302 following sunitinib significantly increased the efficacy of sunitinib in these models. In this phase 1 dose escalation study, TH-302 was combined with standard dose sunitinib. Methods: Eligible patients (pts) for the study (NCT01381822) had advanced RCC, GIST or PNET tumors, evaluable disease by RECIST, ECOG ≤2 and acceptable hematologic, hepatic and renal function. Pts received TH-302 in combination with standard full doses of 50 mg PO sunitinib daily from Day 1 to Day 28 of a 6 week cycle. TH-302 was administered IV on Days 8, 15 and 22. TH-302 starting dose was 240 mg/m2. The study objectives were to determine the MTD, DLTs and RP2D and to evaluate the safety and preliminary efficacy of TH-302 when used in combination with sunitinib. Results: Ten pts were enrolled. Median age: 63 (range 27-72); Female (5)/ Male (5); ECOG 0 (5); ECOG 1 (5); Primary tumor: RCC (6), GIST (4). Median prior chemotherapies: 3 (range: 0-3) including prior sunitinib in 7 pts. No DLTs were observed in the 3 pts at the 240 mg/m2 cohort and 1 pt of 5 DLT evaluable in the 340 mg/m2 cohort had a DLT of stomatitis. Eight pts discontinued (progressive disease (6), pursued other treatment options, adverse event unrelated to study drugs). Three pts had a study drug related SAE (neutropenic sepsis, anemia, hyperthyroidism). Common TH-302 related AEs were nausea and mucosal toxicity and were mostly grade 1 or 2. Grade 3/4 thrombocytopenia and neutropenia were reported in 4 pts and 3 pts, respectively. One of 4 (25%) pts with GIST had a confirmed PR and 3 of 4 (75%) pts with RCC had PRs including 2 with confirmed PRs. Conclusions: TH-302 can be administered in combination with full dose sunitinib. Mucositis was dose limiting. There is preliminary evidence of activity of TH-302 in combination with sunitinib in RCC. Clinical trial information: NCT01381822. Less

5,32...llegando al siguiente soporte!
Tocando ya el soporte de 5,30...ojito a ver que pasa.

es el abstract del ASCO. Hay 3 , os los colgue ayer .

Yo es que tengo ya un cacao de noticias,fechas,soportes y resistencias que voy a necesitar un lapiz y papel para no liarme.
Gracias por la aclaracion

Pues esperate a que las fases I crezcan y cobren relevancia las Fases II y tengamos que estar pendientes de 15 indicaciones... si es que el pipeline es tocho tocho

lápiz y papel, ahora hay unos aparatejos con una fruta detrás, ande vassssssss.

Framus, me gustaria saber tu opinion sobre algo que se me pasa por la cabeza cada vez que hay una conference de este tipo. O son muy muy muy malos haciendo 'presentaciones,lo cual por si mismo es patetico o es que ellos mismos saben que tienen una especie de bufo farmaceutico,es decir,que es como un sufle que ha crecido todo lo que ha podido,pero que cuando alguien abra el horno y le clave el cuchillo para ver que hay dentro se va a encontrar aire.